Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

20260 citationsJournal Articlediamond Open Access

Authors

Arda Can Cetindag · Charité - Universitätsmedizin Berlin

Carola G. Schipke · Charité - Universitätsmedizin Berlin

Hermann Esselmann · University of Göttingen

Niels Kruse · University of Göttingen

Jens Wiltfang · German Center for Neurodegenerative Diseases

Anja Schneider · University Hospital Bonn

Klaus Fliessbach

Abstract

Plasma GFAP is a sensitive, minimally invasive biomarker with diagnostic relevance for amyloid detection and prognostic relevance for clinical progression in early AD.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research S100 Proteins and Annexins

Publication Details

Published in: The Journal of Prevention of Alzheimer s Disease

Volume 13, Issue 5, pp. 100544-100544

DOI: 10.1016/j.tjpad.2026.100544

Field-Weighted Citation Impact: 0.00

Command Palette

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

Authors

Abstract

Topics & Keywords

Publication Details